Trial · NCT03325959
Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome
NCT03325959, Not applicable, Completed, Assaf-Harofeh Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome. Trials, record NCT03325959. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03325959
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome
- NCT number
- NCT03325959
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 76 participants, actual
- Lead sponsor
- Assaf-Harofeh Medical Center
- Conditions
- Fibromyalgia, Hyperbaric Oxygen
- Interventions
- Hyperbaric oxygen therapy (HBOT) treatment, Cymbalta / Lyrica treatment, Crossover Hyperbaric oxygen therapy
- First posted
- 2017-10-30
- Last updated
- 2026-04-22
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual analogue Scale (VAS) | at 3 months | The primary end point of the study will be the measurement of daily pain on a (0-10) Visual analogue Scale |
| Primary | Visual analogue Scale (VAS) | at 6 months | The primary end point of the study will be the measurement of daily pain on a (0-10 scale) Visual analogue Scale |
| Secondary | Global Pain Scale (GPS) | baseline, at 3 months, at 6 months | Fibromyalgia syndrome symptoms questionnaire named Global Pain Scale (GPS) questionnaire (0-100 scale) |
| Secondary | Patient global impression of change | baseline, at 3 months, at 6 months | Fibromyalgia syndrome symptoms questionnaire named: Patient global impression of change (yes/no) |
| Secondary | Fibromyalgia Impact Questionnaire | baseline, at 3 months, at 6 months | Fibromyalgia syndrome symptoms questionnaire named: Fibromyalgia Impact Questionnaire - FIQ (Hebrew version) (0-100 scale) |
| Secondary | Wide Spread Pain Index | baseline, at 3 months, at 6 months | Fibromyalgia syndrome symptoms questionnaire named:Wide Spread Pain Index (WPI) Fibromyalgia syndrome symptoms questionnaire named:Wide Spread Pain Index (scale 0-19) |
| Secondary | Symptom Severity Scale | baseline, at 3 months, at 6 months | Fibromyalgia syndrome symptoms questionnaire named:Symptom Severity Scale (SSS) (scale 0-12) |
| Secondary | SF-36 questionnaire | baseline, at 3 months, at 6 months | Quality of life questionnaire named short-form 36 (SF-36) (scale 0-100) |
| Secondary | Medical Outcome Sleep Scale | baseline, at 3 months, at 6 months | Sleep qualtiy questionnaire named: Medical Outcome Sleep Scale (MOS) questionnaire (0-100 scale) |
| Secondary | Beck Depression Inventory | baseline, at 3 months, at 6 months | Depression questionnaire named Beck Depression Inventory (BDI-II) (scale 0-63) |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03325959
GET https://conductscience.org/api/trials/v1/NCT03325959/registered?page=2